A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine
- 1 June 2004
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Vaccines
- Vol. 3 (3), 249-267
- https://doi.org/10.1586/14760584.3.3.249
Abstract
Hepatitis A and B are two of the most common vaccine-preventable liver diseases and continue to be a significant cause of morbidity and mortality worldwide, with their severity related to the individual's age upon initial infection. Twinrix (GlaxoSmithKline), a combined vaccine providing protection against both hepatitis A and B, has been available in more than 72 countries worldwide since 1997. This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination.Keywords
This publication has 46 references indexed in Scilit:
- Travelers' Knowledge, Attitudes, and Practices on Prevention of Infectious Diseases: Results from a Pilot StudyJournal of Travel Medicine, 2006
- Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: Sixteen years after newborn vaccination program in TaiwanJournal of Medical Virology, 2003
- Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patientsHepatology, 2001
- Hepatitis A among health workers in Paris hospitalsJournal of Medical Virology, 1999
- Factors Associated With Hepatitis B Vaccination Among Men Having Sexual Relations With Men in Montreal, Quebec, CanadaSexually Transmitted Diseases, 1999
- Immunogenicity and protectivity of a new liposomal hepatitis A vaccineVaccine, 1997
- Increased risk of hepatitis A among female day-nursery workers in BelgiumVaccine, 1994
- Prevalence and Incidence of Viral Hepatitis in Health Workers in the Prehepatitis B Vaccination EraAmerican Journal of Epidemiology, 1992
- Hepatitis A immunisation.BMJ, 1991
- Hepatitis A.BMJ, 1991